Quick answer
What is Survodutide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Survodutide is a peptide, grouped on this site under Incretin receptor agonists, and the 12 research records kept here are 2 from studies in rats or mice, 6 from trials in people and 4 that do not state what kind of study it is.
The literature search returned 90 records. This site keeps 12 of them, which is 13 per cent of what came back.
What it is
This site puts it in the Incretin receptor agonists group.
A glucagon receptor and GLP-1 receptor dual agonist, per the retrieved records.[1, 2]
Stated in the titles of the cited 2022 Molecular Metabolism and 2024 Lancet Diabetes and Endocrinology papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 6 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 78 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular metabolism (2022). pmid:36356832
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The lancet. Diabetes & endocrinology (2024). pmid:38330987